| Gene symbol | FOXP3 | Synonyms | AIID, DIETER, IPEX, JM2, PIDX, XPID | Type of gene | protein-coding |
| Chromosome | X | Map location | Xp11.23 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | forkhead box P3 | ||||
| GTO ID | GTC2420 |
| Trial ID | NCT04504669 |
| Disease | Clear Cell Renal Cell Carcinoma | Squamous Cell Carcinoma | Small Cell Lung Cancer | Triple-Receptor Negative Breast Cancer | Gastroesophageal Cancer | Lung Non-Small Cell Carcinoma | Melanoma | Cervical Cancer |
| Altered gene | FOXP3 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | AZD8701 |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase I First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination With Durvaluamb (MEDI4736) in Participants With Advanced Solid Tumours. |
| Year | 2020 |
| Country | Canada|France|Spain|United States |
| Company sponsor | AstraZeneca |
| Other ID(s) | D9950C00001|04504669|2019-004539-22 |
| Vector information | |||
|
|||
| Cohort1: AZD8701 | |||||
|
|||||
| Cohort2: AZD8701_Durvalumab | |||||
|
|||||